Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Sacituzumab govitecan-hziy (SG)|DRUG: Pembrolizumab|DRUG: Capecitabine
Sponsor: Gilead Sciences
Collaborators: Alliance Foundation Trials, LLC.